Previous 10 | Next 10 |
Autolus Therapeutics ([[AUTL]] +8.5%) announces publication of data from Phase 1 study evaluating AUTO6 (1RG-CAR T) in childhood neuroblastoma, in Science Translational Medicine. The trial was sponsored and run by Cancer Research UK’s Centre for Drug Development.New results h...
- Findings from the Phase 1 study provide evidence that AUTO6 induces clinical activity in this solid tumor setting without inducing on-target off-tumor toxicity - AUTO6NG builds on this approach utilizing the same GD2 CAR alongside additional programming modules to enhance the efficacy...
Autolus - a developer of next-generation programmed T cell therapies - has shown continued progress in advancing its anti-cancer pipeline. AUTO1 has entered a pivotal trial for ALL and may achieve regulatory approval by 2022, while, for AUTO3, an outpatient cohort has been initiated i...
LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data pr...
Autolus Therapeutics PLC (AUTL) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 ET Company Participants Lucinda Crabtree - VP, IR & Corporate Communications Christian Itin - Chairman & CEO Andrew Oakley - CFO & SVP Conference Call Participants James Birchenough - Wells F...
Autolus Therapeutics (AUTL): Q3 GAAP EPS of -$0.72 misses by $0.02.License Revenue of $0.24MPress Release For further details see: Autolus Therapeutics EPS misses by $0.02
LONDON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the third quarter ended September 30, 2020. ...
LONDON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2020 financial results and operational highlights...
Autolus Therapeutics (NASDAQ: AUTL ) announced new data highlighting progress on AUTO3, the company’s CAR T cell therapy being investigated in the ALEXANDER study, a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma, during the European Society for Medica...
- AUTO3 shows promise of a highly differentiated product profile Conference call and webcast to be held Friday, September 18, 2020 at 8:00 am EDT / 1:00 pm BST LONDON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopha...
News, Short Squeeze, Breakout and More Instantly...
Autolus Therapeutics plc Company Name:
AUTL Stock Symbol:
NASDAQ Market:
Autolus Therapeutics plc Website:
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights befo...
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes 40% patients are in ongoing remission without subsequent stem cell transplant (SCT) or other intervention Ongoing CAR T persistence was associated wi...